| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Ibrutinib is a white or white solid, soluble in dimethyl sulfoxide, insoluble in water; It is a small molecule BTK inhibitor that can covalently bind to cysteine residues in the active center of BTK, thereby inhibiting its activity. According to lu for his can inhibit malignant B lymphocyte proliferation and survival in the body.
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor used to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL are B-cell non-Hodgkin's lymphomas, which are refractory and easy to relapse. Commonly used chemotherapy and immunotherapy are not targeted, and grade 3 or 4 adverse reactions often occur. Ibrutinib can be targeted to bind with BTK necessary for the formation, differentiation, information transmission and survival of B lymphocytes, irreversibly inhibit the activity of BTK, and effectively inhibit the proliferation and survival of tumor cells; and it is absorbed rapidly after oral administration, 1~ The maximum blood drug concentration reached 2 hours, and the adverse reaction is classified as 1 or 2, which will become a new choice for the treatment of CLL and MCL.
| Item | Test Standard | Testing Result | |
| Assay | 99% | Complies | |
| Apperence | White Powder | Complies | |
| Particle Size | 100% pass 80 mesh | Complies | |
| Oder | Characteristic | Complies | |
| Taste | Characteristic | Complies | |
| Loss on Drying | ≤5.0% | 2.20% | |
| Residue on Ignition | ≤0.1% | 0.05% | |
| Residual | ≤0.1% | Complies | |
| Residual Ethanol | ≤0.5% | Complies | |
| Heave Mentals | ≤10ppm | Complies | |
| Na | ≤0.1% | <0.1% | |
| Pb | ≤3 ppm | Complies | |
| Total Plate | <1000CFU/g | Complies | |
| Yeast & Mold | <100 CFU /g | Complies | |
| E. Coli | Negative | Complies | |
| Salmonella | Negative | Complies | |
){kind=link}